CVS Health raises 2026 earnings and cash flow guidance after strong Q2 revenue and profit growth

CVS Health reported a 7.3% increase in total revenues to $106.1 billion for Q2 2026, with GAAP diluted EPS rising to $2.31 from $0.80 a year ago. Adjusted EPS also grew to $2.58, driven by improved margins in its Health Care Benefits segment. The company generated $10.6 billion in cash flow year-to-date and raised its full-year 2026 guidance for GAAP EPS to $6.84-$7.04 and adjusted EPS to $7.90-$8.10, reflecting strong performance across segments despite cautious outlook on costs and macro risks. CVS is expanding its healthcare services, including GLP-1 therapy support and AI-driven claims processing, aiming to enhance customer access and operational efficiency.